A Phase 1, Open-Label, Dose-Escalation, Multidose Study of MDX-1411 Administered Every 7 Days in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma.

Trial Profile

A Phase 1, Open-Label, Dose-Escalation, Multidose Study of MDX-1411 Administered Every 7 Days in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2009

At a glance

  • Drugs MDX 1411 (Primary)
  • Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb; Medarex
  • Most Recent Events

    • 14 Oct 2009 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 26 Jun 2009 Actual end date (May 2009) and trial locations (Canada, USA) added as reported by ClinicalTrials.gov.
    • 26 Jun 2009 Planned end date changed from 1 Nov 2010 to 1 Mar 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top